Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury

Patent metadata

Field	Value
Publication number	US-10322159-B2
Application number	US-201615158005-A
Country	US
Kind code	B2
Filing date	May 18, 2016
Priority date	Jul 9, 2010
Publication date	Jun 18, 2019
Grant date	Jun 18, 2019

Abstract

The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods provide administering aromatic-cationic peptides in effective amounts to prevent or treat an anatomic zone of no re-flow in mammalian subjects. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

First claim

What is claimed is:

1. A method for treating a zone of hemorrhage in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof, thereby treating the zone of hemorrhage in the subject.

2. The method of claim 1 , further comprising the step of performing a revascularization.

3. The method of claim 1 , wherein the subject is suffering from a zone of hemorrhage associated with a tissue selected from the group consisting of cardiovascular tissue, skeletal muscle tissue, cerebral tissue, and renal tissue.

4. The method of claim 2 , wherein the subject is administered the peptide prior to the revascularization procedure, after the revascularization procedure, during and after the revascularization procedure, or continuously before, during, and after the revascularization procedure.

5. The method of claim 4 , wherein the subject is administered the peptide for at least 3 hours after the revascularization procedure, for at least 5 hours after the revascularization procedure, for at least 8 hours after the revascularization procedure, for at least 12 hours after the revascularization procedure, or for at least 24 hours after the revascularization procedure.

6. The method of claim 4 , wherein the subject is administered the peptide starting at least 8 hours before the revascularization procedure, starting at least 4 hours before the revascularization procedure, starting at least 2 hours before the revascularization procedure, starting at least 1 hour before the revascularization procedure, or starting at least 10 minutes before the revascularization procedure.

7. The method of claim 1 , wherein the subject is suffering from a myocardial infarction or a stroke, or is in need of angioplasty.

8. The method of claim 2 , wherein the revascularization procedure is selected from the group consisting of balloon angioplasty, insertion of a bypass graft, insertion of a stent, percutaneous transluminal coronary angioplasty, and directional coronary atherectomy.

9. The method of claim 2 , wherein the revascularization procedure is removal of an occlusion.

10. The method of claim 2 , wherein the revascularization procedure is administration of one or more thrombolytic agents.

11. The method of claim 10 , wherein the one or more thrombolytic agents are selected from the group consisting of tissue plasminogen activator, urokinase, prourokinase, streptokinase, acylated form of plasminogen, acylated form of plasmin, and acylated streptokinase-plasminogen complex.

Assignees

• Stealth Biotherapeutics Corp
• Good Samaritan Institute For Res And Education

Inventors

• Wilson D Travis
• Borow Kenneth
• Kloner Robert A
• Hale Sharon

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K38/07 Primary

  Tetrapeptides · CPC title